Goodbody Health Launches Mobile Phlebotomy Service


Health Limited

(“Goodbody Health”, or the “Company”)

Goodbody Health launches mobile phlebotomy service


Goodbody Health (AQSE: GDBY) is pleased to announce the expansion of services through partnerships and the launch of its new mobile phlebotomy service to develop and increase the reach of the phlebotomy services that Goodbody is able to offer. This allows testing to be undertaken in the patients home or other convenient location and meets the needs of those unable to travel. This has proven to be very successful with over 120 applicant phlebotomists for the platform and patients choosing this sample collection method. This sample collection method will be available for partners in the not-too-distant future. This is a significant piece of technology that has been developed over 4 months.


Following the Company announcement on January 26th, 2023, that it has partnered with Datar Cancer Genetics (“Datar”), a world-leading liquid biopsy company, to offer its innovative Circulating Tumour Cell (“CTC”) based multi-cancer screening solution Trucheck, the rollout of these innovative tests has started to show good progress. The Company has had significant interest in the product through the initial soft-launch phase, demonstrating that this could be a significant revenue stream for the Company with 25 tests sold to date generating strong revenue. The Company has also established a distribution infrastructure to resell the tests to other private medical providers to drive additional volume and uptake has been positive.


Following the Company announcements on January 31st and February 15th, 2023, that the Company had signed phlebotomy contracts with 5 other testing suppliers who wish to use Goodbody Clinics as a phlebotomy partner, 4 more contracts have been signed with the following partners:


  • Balance My Hormones – Hormone Replacement Provider
  • Optimale – Hormone Replacement Provider
  • Manual – Blood and Wellness Testing Provider
  • Cancer Screening Trust

George Thomas, Chief Executive Officer, said: “The Company is excited to develop new product opportunities, integrate with other providers and supply a more flexible mobile service. We believe this market will grow for all participants as UK health services delivery, including diagnostics, is delivered through partnerships and innovative third party solutions.”

The Directors of the Company accept responsibility for the contents of this announcement.

George Thomas
Chief Executive Officer
Goodbody Health Limited
+44 (0) 20 7971 1255
[email protected]

AQSE Corporate Advisor
Peterhouse Capital Limited
Guy Miller / Mark Anwyl
+44 (0) 20 7469 0930

Anne Tew
Chief Financial Officer
Goodbody Health Limited
+44 (0) 20 7971 1255
[email protected]

Notes to Editors:

Health Limited (AQSE: GDBY and OTCQB: GDBYF) is an aggregator of the
highest quality, most innovative range of health 
wellness services and products using
the latest technology.  With over 52 products today, tests include blood, genetic, covid and other diagnostic
solutions to meet today’s fast evolving consumer expectations
 with more than 200,000 tests completed to
date. A comprehensive portfolio of CBD based products complement the
wellness range.

as a trusted distributor and retailer of accredited
wellness products and diagnostic services, provid
es a unique ‘frontline’ healthcare service in the
local community 
with expertise to enable customers to manage their health care digitally and make considered choices for their ‘health span’. Our
products and services grow local level amenities through 
a network
of over 200 independent community providers
offering much needed revenue to pharmacists and 
others local
providers, while alleviating pressure on the NHS.


Useful Website and social media links:

Share on

Published on